Practical Considerations for Immunotherapy in Stage 3 NSCLC – OncLive
OncLive |
Practical Considerations for Immunotherapy in Stage 3 NSCLC
OncLive In fact, if you look at the subgroup analysis of the PACIFIC trial, you can observe that the most benefit is for patients who started immediately with the immunotherapy. However, in some cases, you have to wait because maybe the patient still has some … |
